Cellosaurus SW1710 (CVCL_1721)

Cell line name SW1710
Synonyms SW-1710; SW 1710
Accession CVCL_1721
Resource Identification Initiative To cite this cell line use: SW1710 (RRID:CVCL_1721)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: UBC-40 urothelial bladder cancer cell line index.
From: Scott and White Clinic; Temple; Texas; USA.
Doubling time: ~25-32 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations TERT c.228C>T (-124C>T); in promoter (PubMed=24035680).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; PubMed=27270441

Markers:
AmelogeninX
CSF1PO11,12
D13S31712
D16S5398,11
D5S81812
D7S8208,11
TH017,10 (Cosmic-CLP)
7,8,9.3 (DSMZ)
7,9.3 (PubMed=27270441)
TPOX9,11
vWA16,17
Web pages https://www.synapse.org/UC25
Publications

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6744315
Kyriazis A.A., Kyriazis A.P., McCombs W.B. III, Peterson W.D. Jr.
Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice.
Cancer Res. 44:3997-4005(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=11921286; DOI=10.1002/gcc.10050
Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N., Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Genes Chromosomes Cancer 34:86-96(2002)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052
Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M., van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A., Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G., Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C., Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Eur. Urol. 65:360-366(2014)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=26621286; DOI=10.1186/s12864-015-2227-4
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:1019-1019(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

Cross-references
Cell line collections DSMZ; ACC-426
Cell line databases/resources CCLE; SW1710_URINARY_TRACT
Cosmic-CLP; 909749
GDSC; 909749
LINCS_LDP; LCL-1719
Ontologies CLO; CLO_0009213
Biological sample resources BioSample; SAMN03473594
Chemistry resources ChEMBL-Cells; CHEMBL3308804
ChEMBL-Targets; CHEMBL1075590
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM136258
GEO; GSM763023
GEO; GSM827181
GEO; GSM887670
GEO; GSM888762
GEO; GSM1374921
GEO; GSM1574554
GEO; GSM1670504
Other Wikidata; Q54971090
Polymorphism and mutation databases Cosmic; 715750
Cosmic; 760483
Cosmic; 845572
Cosmic; 909749
Cosmic; 1016890
Cosmic; 1046685
Cosmic; 1285129
Cosmic; 1285989
Cosmic; 2037957
Cosmic; 2050463
Cosmic; 2057458
Cosmic; 2444251
Cosmic; 2686115